档案网站的结论：胰岛素在1型糖尿病中是不可或缺的；在2型糖尿病中，证据支持谨慎采用强化剂量，在升级胰岛素治疗之前优先考虑二甲双胍、减重和饮食改变，并以适度而非接近正常的糖化血红蛋白（HbA1c）为目标；这并不等于拒绝胰岛素。
原始表述
الخلاصة: الإنسولين ضرورة لا غنى عنها للنوع الأول، أما في النوع الثاني فالأدلة تدعو إلى التحفظ في الجرعات وتفضيل الميتفورمين والتدخل الغذائي قبل تكثيف الإنسولين، لا إلى رفض الإنسولين كاملًا كما يطرح العوضي.
按来源为原话. 译文由本项目提供；以阿拉伯语原文为准。
译文
档案网站的结论：胰岛素在1型糖尿病中是不可或缺的；在2型糖尿病中，证据支持谨慎采用强化剂量，在升级胰岛素治疗之前优先考虑二甲双胍、减重和饮食改变，并以适度而非接近正常的糖化血红蛋白（HbA1c）为目标；这并不等于拒绝胰岛素。
出处
- 来源状态
- 档案网站编辑
- 归属
- Archive editors (not Elawady)
- 出处
- https://eltayebat.com/rule/insulin-injections/
- 归属的不确定性
- Editorial narrative and study selection written by the archive operators.
- 涉及人群
People with diabetes
- Elawady 设定的地域限制
none found
科学评估
基本正确 – 核心内容正确，但有局限或细微不准确之处。
证据确定性: 高 – 进一步研究极不可能改变该评估。
1. 说法是什么？
Insulin essential in type 1; caution and moderation in type 2; not a rejection of insulin.
2. 哪些内容可证实是正确的？
ADA 2026: an HbA1c goal <7% is appropriate for many adults, less stringent goals for people with significant limitations, and hypoglycaemia-causing drugs (insulin, sulfonylureas) should be deintensified where risks outweigh benefits (I-INS-10). Metformin reduced diabetes-related endpoints and mortality in overweight patients in UKPDS 34 (I-ODD-01). Insulin is essential in type 1 diabetes (I-ODD-16). This archive conclusion contradicts Elawady's own position that insulin should be avoided.
3. 哪些内容是错误或夸大的？
The archive omits that current guidelines recommend SGLT2 inhibitors or GLP-1 receptor agonists independently of HbA1c in people with cardiovascular disease, heart failure or kidney disease (I-ODD-16, I-ODD-17), and that insulin should be started regardless of other therapy when HbA1c >10%, glucose >=300 mg/dL or catabolic features are present (I-ODD-16).
4. 哪些内容仍不明确？
Which HbA1c target and which order of drugs is best for an individual depends on age, other diseases, hypoglycaemia risk and preferences; guidelines give ranges rather than one rule. Whether the archive's emphasis on caution with insulin leads readers to delay insulin when it is needed was not studied.
5. 哪些研究支持该说法？
A-INS-01, A-INS-19, I-INS-10, I-ODD-01, I-ODD-16, I-ODD-17, I-INS-122 (RCTs: insulin in T2D does not change mortality but increases severe hypoglycaemia), I-INS-133 ('lifelong insulin therapy is essential in type 1 diabetes'), I-INS-131 (youth T2D: maximise non-insulin therapy; reduce insulin when goals met), I-DIAB-115 (NICE: remission programmes).
6. 哪些研究与该说法相矛盾？
None material.
7. 对德国和欧洲而言情况如何？
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. 关于埃及的已知情况是什么？
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. 合理的实际结论是什么？
这是一个合理的总结，与归于 Elawady 的那些说法有根本区别。
评估详情
- 证据确定性的依据
Consistent with ADA Standards 2026 and ADA/EASD consensus. Not fully TRUE because current guidelines also prioritise SGLT2 inhibitors and GLP-1 receptor agonists with proven cardiorenal benefit and recommend early insulin when glucose is very high or catabolic features are present.
- 来源质量
Archive editorial; it explicitly distances itself from Elawady's rejection of insulin.
- 地区可推广性
Universal.
- 说法的地域范围
- 普遍性（生物学/医学）
- 最近审核
- 2026年10月26日 初步
科学证据详解
有充分科学证据支持 – 该说法与一致的高质量证据相符。
研究问题: Is the archive's conclusion correct that insulin is indispensable in type 1 diabetes and that in type 2 diabetes caution with intensive insulin, prioritising metformin, weight loss and diet, and moderate HbA1c targets are evidence-based?
研究问题详解 (PICO)
- 人群
- People with type 1 and type 2 diabetes
- 干预或暴露
- Insulin strategy as summarised by the archive
- 对照
- Current guidelines
- 地域范围
- universal biology
- 结局指标
- Agreement with guidelines
- Mortality and hypoglycaemia with insulin in T2D
研究结果按作者报告呈现。我们的评估见下文。
哪些证据支持该说法？
European and US consensus 2026 on type 1 diabetes in adults
Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z 指南 / 立场声明已核查全文新增ADA/EASD 2026 T1D consensus.
- 实际结果
- 'Lifelong insulin therapy is essential in type 1 diabetes'.
- 方法学质量
- high (guideline)
- 相关性
- direct
Insulin in type 2 diabetes: what randomised trials show
Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z Meta分析已核查摘要新增RCT meta-analysis of insulin in T2D.
- 实际结果
- No mortality effect; severe hypoglycaemia RR 1.70.
- 方法学质量
- high
- 相关性
- direct
- 局限
- Trials to 2013.
ADA guideline 2026: blood sugar goals and emergencies
American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006 指南 / 立场声明已核查全文ADA 2026 section 6.
- 实际结果
- A1C <7% for many; less stringent goals where appropriate; deintensify hypoglycaemia-causing drugs.
- 方法学质量
- high (guideline)
- 相关性
- direct
哪些证据不支持该说法？
未发现反对该说法的高质量证据。
总体证据说明了什么？
基于上述研究的编辑评估——其本身并非研究结果。
哪种观点有更好的证据支持？
The archive's conclusion matches guidelines; it omits that SGLT2 inhibitors/GLP-1 RAs are prioritised for cardiorenal protection and that insulin is indicated early when glucose is very high or catabolic.
为什么有些研究权重更大
Guidelines and RCT meta-analysis.
因果关系是否已确立？ 不适用 Assessment of a summary statement.
仍存在的不确定性
Individual targets vary.
合理的结论
Mostly true.
这是否取决于国家？
- 一般生物学效应
- Insulin physiology, autoimmune type 1 diabetes and ketoacidosis are universal human biology.
- 饮食习惯
- Egyptian and European diets differ, but no dietary pattern replaces insulin in insulin-deficient diabetes.
- 食品原产地
- Not relevant.
- 污染物
- Not relevant.
- 本国生产条件
- Not relevant.
- 法律规则
- Insulin is an essential medicine (WHO list) in Egypt and the EU; prescription rules not relevant to the scientific question.
- 实际监测数据
- Egyptian/Middle Eastern data show severe DKA is common at presentation in children (I-INS-115, I-INS-114); no data on outcomes among Tayebat followers.
足以改变结论的地区差异没有可靠数据支持。
统计复核
- CI symmetry – Mortality RR 0.99 (0.92-1.06) symmetric 已重新计算
总体证据的确定性（GRADE，简化版）
- 主要结局
- Agreement of the archive conclusion with guideline evidence
- 起始等级
- 高（随机试验）
- 结果
- 高
由单名审查者参照 GRADE 方法进行的简化评估；并非正式的 GRADE 专家组评估。GRADE 评价的是针对某一结局的整体证据，而非单项研究。
已核查的临床指南和官方声明
- ADA/EASD: The management of type 1 diabetes in adults: updated 2026 consensus report (2026) · 原始文献
'Lifelong insulin therapy is essential in type 1 diabetes'; all individuals need glucose and ketone testing supplies; insulin omission or under-dosing is a DKA precipitant. - ADA: 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026 (2026) · 原始文献
People at risk for DKA should have ketone testing tools and sick-day advice; people on intensive insulin therapy should not stop or hold basal insulin even if not eating; caution with near-normal A1C goals in long-standing T2D using hypoglycaemia-prone drugs (ACCORD). - ADA: 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026 (I-ODD-16) (2026) · 原始文献
'Insulin treatment is essential for individuals with type 1 diabetes'; insulin to be considered in T2D when A1C >10%, glucose >=300 mg/dL or catabolic features (as recorded for I-ODD-16). - ADA: 14. Children and Adolescents: Standards of Care in Diabetes-2026 (2026) · 原始文献
For type 1 diabetes 'insulin therapy is paramount'; rec 14.36: start insulin in ketoacidosis; thyroid screening because of autoimmune clustering; in youth T2D maximise non-insulin therapy and consider reducing insulin when goals are met (14.39-14.40). - NICE: NG28 Type 2 diabetes in adults: management (last updated 18 February 2026) (2026) · 原始文献
Low-energy and very-low-energy diets via the NHS Type 2 Diabetes Path to Remission Programme (1.3.4); evidence on stopping/switching medicines is limited (research recommendation).
检索策略
本次审查的文献检索记录（检索式采用原数据库语法）。
| 数据库 | 日期 | 检索式 | 检索目标 | 命中数 | 纳入数 |
|---|---|---|---|---|---|
| PubMed | 2026年10月26日 | "type 2 diabetes" AND (deintensification OR "de-intensification") AND insulin AND (older OR hypoglycemia) AND (guideline OR consensus) | 双向 | 4 | |
| PubMed | 2026年10月26日 | Erpeldinger S[au] AND insulin | 双向 | 2 | |
| Guideline websites (NICE) | 2026年10月26日 | Fetched https://www.nice.org.uk/guidance/ng28/chapter/Dietary-advice-and-interventions (+ Insulin-based-treatments, Individualised-care) | 指南 | 3 | |
| Springer (publisher full text) | 2026年10月26日 | Fetched https://link.springer.com/article/10.1007/s00125-026-06833-z (ADA/EASD 2026 T1D consensus) | 指南 | 1 | |
| PMC (publisher full text) | 2026年10月26日 | Fetched ADA Standards of Care 2026 sections 2, 6, 8, 10, 14, 16 at pmc.ncbi.nlm.nih.gov/articles/PMC12690183, PMC12690178, PMC12690172, PMC12690187, PMC12690182, PMC12690180 | 指南 | 6 |
核查深度如何？
10 项相关研究：6 项核查了全文（其中 0 项进行了结构化偏倚风险评估），4 项基于摘要核查，0 项仅核查了文献信息。 尚未进行由两名独立审查者完成的正式评估，也尚未进行独立的人类专家审核。
最近一次科学审核: 2026年10月26日
评定结论的变更历史
- 2026年10月25日 · 第 1 阶段 · 初始评估: 基本正确 (高)
- 2026年10月26日 · 第 4 阶段（系统证据审查） · 在扩展证据后重新审查；评定结论不变: 基本正确 (高)
New guideline and meta-analytic evidence confirm the archive's summary.
新来源: I-INS-122 I-INS-131 I-INS-133 I-DIAB-115
通俗解释
该档案网站自己的总结说，胰岛素在1型糖尿病中能挽救生命，而在2型糖尿病中，医生应避免把血糖压得过低，并应从二甲双胍、减重和饮食入手。这与当前的医学指南一致，指南还推荐使用能保护心脏和肾脏的较新药物。
与该说法相关的研究
支持该说法的研究 (10)
-
Very aggressive blood sugar lowering in high-risk type 2 diabetes
Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743随机对照试验被 Tayebat 档案网站引用已核查全文★ 关键研究Pushing HbA1c below 6% increased deaths by about one-fifth and did not reduce heart attacks or strokes significantly.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Does targeting a normal HbA1c (<6.0%) reduce cardiovascular events in type 2 diabetes with high cardiovascular risk?
- 研究是如何开展的？
Multicentre randomised controlled trial (open-label treatment strategies), mean 3.5 years of intensive therapy
- 研究了多少人、动物或样本？
10,251; Type 2 diabetes, mean age 62.2, median HbA1c 8.1%, established CVD or additional risk factors
- 实际发现了什么？
More deaths (HR 1.22) and more severe hypoglycaemia with intensive therapy; primary CV outcome not significantly reduced.
- 观察到的效应有多大？
HR 1.22 (1.01-1.46) all-cause death; HR 0.90 (0.78-1.04) primary outcome
- 研究结果对日常生活意味着什么？
Very strict sugar targets are not good for everyone, especially older people with heart disease.
- 该研究有哪些局限？
Strategy trial: cannot attribute harm to a specific drug; Intensive arm stopped early; High-risk population; not generalisable to early diabetes
- 它对 Elawady 的具体说法说明了什么？
Core evidence that near-normal HbA1c targets can harm high-risk type 2 patients (C-INS-04).
- 研究结果是否适用于德国和欧洲？
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- 从该研究中明确不能得出什么结论？
That insulin specifically caused the deaths, or that lowering high glucose to moderate targets is harmful.
-
Adding metformin to insulin
Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133随机对照试验被 Tayebat 档案网站引用已核查摘要Metformin improved sugar control and reduced insulin need and weight gain.
该研究是否支持这一具体说法？ 是 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Metformin added to intensive insulin in type 2 diabetes
- 研究是如何开展的？
Double-blind placebo-controlled RCT
- 研究了多少人、动物或样本？
390; Insulin-treated type 2 diabetes
- 实际发现了什么？
Better control, less insulin, less weight gain.
- 观察到的效应有多大？
GHb -0.7%
- 研究结果对日常生活意味着什么？
Combination lowers insulin needs.
- 该研究有哪些局限？
Short duration; Dropouts higher with metformin
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Dutch data.
- 从该研究中明确不能得出什么结论？
That insulin can be stopped.
-
ADA guideline 2026: blood sugar goals and emergencies
American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006指南 / 立场声明独立交叉核查已核查全文★ 关键研究Most adults should aim for HbA1c below 7%, avoid low sugar, and measure ketones when at risk.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Glycaemic goals, hypoglycaemia and hyperglycaemic crises
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 6)
- 研究了多少人、动物或样本？
not applicable; People with diabetes
- 实际发现了什么？
Individual targets; do not stop basal insulin when not eating.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Moderate targets and safety rules.
- 该研究有哪些局限？
US-centred; Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with EASD guidance.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Metformin in overweight type 2 diabetes (UKPDS 34)
UKPDS Group. Lancet 1998 · PMID 9742977随机对照试验独立交叉核查已核查摘要★ 关键研究Metformin reduced deaths from any cause by about a third over 10 years.
该研究是否支持这一具体说法？ 否 · 方法学质量: 中 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Intensive control with metformin in overweight type 2 diabetes
- 研究是如何开展的？
RCT within UKPDS (UKPDS 34)
- 研究了多少人、动物或样本？
753 (main comparison); Overweight newly diagnosed type 2 diabetes, mean age 53
- 实际发现了什么？
Mortality -36%.
- 观察到的效应有多大？
RR reduction 36% (9-55)
- 研究结果对日常生活意味着什么？
Metformin is protective.
- 该研究有哪些局限？
Small arms; Open-label; Conflicting supplementary result
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Effects in non-overweight patients.
-
ADA guideline 2026: diabetes medicines
American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009指南 / 立场声明独立交叉核查已核查全文★ 关键研究Insulin is essential in type 1 diabetes; SGLT2/GLP-1 drugs are recommended for heart and kidney protection; side effects listed.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Pharmacologic glycaemic treatment
- 研究是如何开展的？
Clinical practice guideline (ADA Standards of Care 2026, Section 9)
- 研究了多少人、动物或样本？
not applicable; People with type 1 and type 2 diabetes
- 实际发现了什么？
See results.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Medicines chosen by benefit-risk.
- 该研究有哪些局限？
Partially read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
Consistent with ADA/EASD consensus.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
ADA/EASD consensus 2022
Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034指南 / 立场声明独立交叉核查已核查摘要Weight management plus heart- and kidney-protective drugs are central to type 2 diabetes care.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Management of hyperglycaemia in type 2 diabetes
- 研究是如何开展的？
ADA/EASD consensus report based on systematic examination of publications since 2018
- 研究了多少人、动物或样本？
not applicable; Adults with type 2 diabetes
- 实际发现了什么？
Cardiorenal protection and weight focus.
- 观察到的效应有多大？
not applicable
- 研究结果对日常生活意味着什么？
Guideline direction.
- 该研究有哪些局限？
Abstract only read
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
EASD co-authored; directly applicable to EU.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
Insulin in type 2 diabetes: what randomised trials show
Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-zMeta分析独立交叉核查已核查摘要★ 关键研究In 20 trials with 18,599 people, insulin did not change the risk of death but caused more severe low blood sugar.
No hard-outcome benefit and more hypoglycaemia in T2D: supports caution with insulin escalation.
该研究是否支持这一具体说法？ 部分支持 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Summarise RCTs of insulin in T2D.
- 研究是如何开展的？
Meta-analysis of 20 RCTs.
- 研究了多少人、动物或样本？
18,599 patients.
- 实际发现了什么？
Mortality unchanged; severe hypoglycaemia +70%.
- 观察到的效应有多大？
RR 0.99 death; 1.70 severe hypoglycaemia.
- 研究结果对日常生活意味着什么？
Insulin does not kill, but low sugar is a real risk; use it carefully.
- 该研究有哪些局限？
Older trials; heterogeneity.
- 它对 Elawady 的具体说法说明了什么？
Refutes 'insulin doubles mortality'; supports caution.
- 研究结果是否适用于德国和欧洲？
Applicable.
- 从该研究中明确不能得出什么结论？
Cannot address insulin in type 1 diabetes, where it is essential.
-
European and US consensus 2026 on type 1 diabetes in adults
Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z指南 / 立场声明独立交叉核查已核查全文★ 关键研究Lifelong insulin is essential in type 1 diabetes, and everyone with type 1 diabetes should be able to test glucose and ketones.
Confirms the archive's 'insulin indispensable in type 1'.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Update guidance on adult T1D care.
- 研究是如何开展的？
Consensus report.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Insulin lifelong and essential; ketone testing for all.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
People with type 1 diabetes must never stop insulin.
- 该研究有哪些局限？
Consensus.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
European (EASD) guidance.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
US diabetes standards 2026: children and adolescents
American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358890 · DOI 10.2337/dc26-S014指南 / 立场声明独立交叉核查已核查全文★ 关键研究Insulin is essential for children with type 1 diabetes; in youth with type 2 diabetes, insulin can be reduced when goals are met.
Youth T2D: maximise non-insulin therapy; reduce insulin when goals met.
该研究是否支持这一具体说法？ 否 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide paediatric diabetes care.
- 研究是如何开展的？
Evidence-graded guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Insulin paramount in T1D; insulin for ketoacidosis.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Children with type 1 diabetes need insulin.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
- 研究结果是否适用于德国和欧洲？
European paediatric guidance (ISPAD, NICE NG18) agrees.
- 从该研究中明确不能得出什么结论？
Not applicable.
-
UK guideline on type 2 diabetes in adults
National Institute for Health and Care Excellence (NICE). NICE guideline 2015指南 / 立场声明独立交叉核查已核查全文★ 关键研究Low-energy diet remission programmes are part of standard UK care for type 2 diabetes.
Diet/weight-loss remission programmes are standard in UK T2D care.
该研究是否支持这一具体说法？ 是 · 方法学质量: 高 · 证据确定性：见该说法的总体评估
研究通俗解读
- 研究人员想了解什么？
Guide T2D care.
- 研究是如何开展的？
Guideline.
- 研究了多少人、动物或样本？
Not applicable.
- 实际发现了什么？
Remission programme recommended.
- 观察到的效应有多大？
Not applicable.
- 研究结果对日常生活意味着什么？
Diet and weight loss come first in type 2 diabetes, under supervision.
- 该研究有哪些局限？
Guideline.
- 它对 Elawady 的具体说法说明了什么？
Supports C-INS-11.
- 研究结果是否适用于德国和欧洲？
UK.
- 从该研究中明确不能得出什么结论？
Not applicable.
该组中没有被标记为关键研究的研究。
与该说法相矛盾或限制该说法的研究 (0)
该组中没有研究。
结果不一或不明确的研究 (0)
该组中没有研究。
地区背景
德国 / 欧盟
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
埃及
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
在我的国家适用什么？
一般科学评估
基本正确 该档案网站的结论与指南大体一致，并与拒绝胰岛素的主张相矛盾。
该说法涉及生物学或医学关系。上述科学评估不论在哪个国家都适用；各国食品数据不会改变这一评估。
参考文献
- Effects of intensive glucose lowering in type 2 diabetes.. Action to Control Cardiovascular Risk in Diabetes Study Group; Gerstein HC et al.. N Engl J Med 2008 · PMID 18539917 · DOI 10.1056/NEJMoa0802743
- Combination of insulin and metformin in the treatment of type 2 diabetes.. Wulffelé MG et al.. Diabetes Care 2002 · PMID 12453950 · DOI 10.2337/diacare.25.12.2133
- 6. Glycemic Goals, Hypoglycemia, and Hyperglycemic Crises: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes* . Diabetes Care 2026 · PMID 41358894 · DOI 10.2337/dc26-S006
- Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.. UKPDS Group. Lancet 1998 · PMID 9742977
- 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes*. Diabetes Care 2026 · PMID 41358900 · DOI 10.2337/dc26-S009
- Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Davies MJ et al.. Diabetes Care 2022 · PMID 36148880 · DOI 10.2337/dci22-0034
- Efficacy and safety of insulin in type 2 diabetes: meta-analysis of randomised controlled trials.. Erpeldinger S et al.. BMC Endocr Disord 2016 · PMID 27391319 · DOI 10.1186/s12902-016-0120-z
- The management of type 1 diabetes in adults. The updated 2026 consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).. Holt RIG et al.. Diabetologia 2026 · PMID 42747450 · DOI 10.1007/s00125-026-06833-z
- 14. Children and Adolescents: Standards of Care in Diabetes-2026.. American Diabetes Association Professional Practice Committee for Diabetes. Diabetes Care 2026 · PMID 41358890 · DOI 10.2337/dc26-S014
- NICE guideline NG28: Type 2 diabetes in adults: management. National Institute for Health and Care Excellence (NICE). NICE guideline 2015